Emcure Pharmaceuticals and Novo Nordisk India have entered into a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India. As part of the agreement, the company will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, semaglutide injection 2.4 mg, in India.
This partnership is part of Novo Nordisk India’s efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. The Poviztra is a second brand of Wegovy. Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
